Last reviewed · How we verify
NCT04976439
Patogenic Mutation in 5 Genes
trial testing co-occuring mutation in Colorectal Cancer in 22 participants. Completed in 14 June 2021.
10 June 2021
Quick facts
| Lead sponsor | Dr Cipto Mangunkusumo General Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 22 |
| Start date | 1 May 2021 |
| Primary completion | 10 June 2021 |
| Estimated completion | 14 June 2021 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- co-occuring mutation
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- APC Gene Mutation — all drugs for APC Gene Mutation →
- TP53 Gene Mutation — all drugs for TP53 Gene Mutation →
- PIK3CA Gene Mutation — all drugs for PIK3CA Gene Mutation →
Sponsor
Dr Cipto Mangunkusumo General Hospital
Who can join
18 and older, any sex, with Colorectal Cancer or APC Gene Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pathogenic mutation profile of colorectal patients specifically in 5 genes, i.e. APC, TP53, PIK3CA, KRAS, and MLH1. Single nucleotide variants identified were synchronized with patients' characteristics.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04976439
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Dr Cipto Mangunkusumo General Hospital trials
Trials by the same sponsor.
- NCT07074548 — Effect of Hydroxytyrosol on NLR, MLR, and SOD in Hypertensive Pregnant Women · NA · completed
- NCT07141940 — Indonesian-Language Application-Based Guided Imagery Therapy for Insomnia and Glycemic Control in Diabetic Patients · NA · completed
- NCT07422116 — Non-Inferiority Test of Mixsafe® Compared to Neopuff® in Providing Respiratory Support to Neonates · NA · completed
- NCT06929793 — Multiple Micronutrients Supplementation on Angiogenesis and Vasculogenesis Factors, and Fetal Biometry · NA · active not recruiting
- NCT07149272 — Lactate Kinetics Analysis Related to Low-Intensity Resistance Exercise · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04976439 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr Cipto Mangunkusumo General Hospital
- Last refreshed: 26 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04976439.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing